{
    "eid": "2-s2.0-85142940973",
    "title": "Updated management for antibody-mediated rejection: Opportunity to prolong kidney allograft survival",
    "cover-date": "2023-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Medicine (all)",
            "@code": "2700",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "ABO incompatibility",
        "antibody-mediated rejection",
        "antihuman leukocyte antigen",
        "donor-specific antihuman leukocyte antibody"
    ],
    "authors": [
        "Natavudh Townamchai",
        "Yingyos Avihingsanon"
    ],
    "citedby-count": 0,
    "ref-count": 43,
    "ref-list": [
        "Identifying the specific causes of kidney allograft loss: A population-based study",
        "Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis",
        "Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts",
        "Causes of kidney graft failure in a cohort of recipients with a very long-time follow-up after transplantation",
        "Survival benefit with kidney transplants from HLA-incompatible live donors",
        "Impact of ABO-incompatible living donor kidney transplantation on patient survival",
        "Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant",
        "Clinical relevance of posttransplant DSAs in patients receiving desensitization for HLA-incompatible kidney transplantation",
        "Quantifying the risk of incompatible kidney transplantation: A multicenter study",
        "Complement-binding anti-HLA antibodies and kidney-allograft survival",
        "Donor-specific antibodies in kidney transplant recipients",
        "IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury",
        "Development of de novo donor-specific HLA antibodies and AMR in renal transplant patients depends on CYP3A5 genotype",
        "Development and outcomes of de novo donor-specific antibodies in low, moderate, and high immunological risk kidney transplant recipients",
        "Chronic allograft injury: An overview of pathogenesis and treatment strategies",
        "Recommended treatment for antibody-mediated rejection after kidney transplantation: The 2019 expert consensus from the Transplantation Society Working Group",
        "Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (Imlifidase) in chronic kidney disease patients",
        "Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation",
        "The bacterial enzyme IdeS cleaves the IgG-Type of B cell receptor (BCR), abolishes BCR-mediated cell signaling, and inhibits memory B cell activation",
        "IgG endopeptidase in highly sensitized patients undergoing transplantation",
        "Imlifidase desensitization in crossmatch-positive, highly sensitized kidney transplant recipients: Results of an international Phase 2 trial (Highdes)",
        "Imlifidase: First approval",
        "Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: Therapeutic implications of IL-6 receptor blockade",
        "Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients",
        "Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation?",
        "Early effects of first-line treatment with antiinterleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation",
        "Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients",
        "A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection",
        "Allorecognition and the spectrum of kidney transplant rejection",
        "The anti-CD38 antibody therapy in multiple myeloma",
        "CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection",
        "Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: Study protocol for a phase 2 trial",
        "HLA desensitization in solid organ transplantation: Anti-CD38 to across the immunological barriers",
        "Clinical outcomes after ABO-incompatible renal transplantation: A systematic review and meta-analysis",
        "ABO-incompatible kidney transplantation in perspective of deceased donor transplantation and induction strategies: A propensity-matched analysis",
        "Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy",
        "ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab",
        "Japanese experience of ABO-incompatible living kidney transplantation",
        "Outcome of ABO-incompatible kidney transplantation using a modified desensitization protocol without plasmapheresis",
        "Effect of rituximab dose on induction therapy in ABO-incompatible living kidney transplantation: A network meta-analysis",
        "Outcome of ABO-incompatible kidney transplantation according to ABO type of transfused plasma: Comparative analysis between 'Universal' AB and donor-type plasma",
        "A novel method of CD31-combined ABO carbohydrate antigen microarray predicts acute antibody-mediated rejection in ABO-incompatible kidney transplantation",
        "Infection risk in the first year after ABO-incompatible kidney transplantation: A nationwide prospective cohort study"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "National Research Council of Thailand"
    ]
}